Literature DB >> 28340875

Angioimmunoblastic T-Cell Lymphoma.

Alessandro Broccoli1, Pier Luigi Zinzani2.   

Abstract

Angioimmunoblastic T-cell lymphoma is a follicular T-helper-derived neoplasm displaying a peculiar morphologic appearance and biological complexity. New mutations have been described that contribute to elucidating the underlying pathogenetic events. The disease behaves aggressively and typically affects elderly patients. The outcomes reported with anthracycline-containing regimens are poor; therefore autologous transplantation in first remission should be offered whenever possible. Newer approaches are urgently needed for relapsed and refractory patients. Newly approved agents show activity in pretreated patients but response durations are short. Innovative induction strategies (CHOP + biologic agent) should be designed to enhance response quality, facilitate transplantation, and prolong survival.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angioimmunoblastic T-cell lymphoma; Autologous stem cell transplantation; Brentuximab vedotin; CHOP; DNMT3A; Follicular T-helper; IDH2; Lenalidomide

Mesh:

Substances:

Year:  2017        PMID: 28340875     DOI: 10.1016/j.hoc.2016.12.001

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  7 in total

Review 1.  Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection.

Authors:  Narittee Sukswai; Joseph D Khoury
Journal:  Curr Hematol Malig Rep       Date:  2019-10       Impact factor: 3.952

2.  [Angioimmunoblastic T-cell lymphoma with fever, arthritis and skin pigmentation: A case report].

Authors:  G Cheng; X Zhang; F Yang; J Y Cheng; Y Y Liu
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2020-12-18

3.  Relapsed angioimmunoblastic T-cell lymphoma with large pericardial effusion.

Authors:  Rahul Sawhney; Randy D Volkmer; Barry Cooper
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-10-25

4.  Application of NanoString technologies in angioimmunoblastic T cell lymphoma.

Authors:  Wonseok Shin; Seyoung Mun; Seungkyu Choi; Kyudong Han
Journal:  Genes Genomics       Date:  2020-03-07       Impact factor: 1.839

5.  Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: A multicenter phase II trial.

Authors:  Yawen Wang; Mingzhi Zhang; Wei Song; Qingqing Cai; Liling Zhang; Xiuhua Sun; Liqun Zou; Huilai Zhang; Lili Wang; Hongwei Xue
Journal:  Am J Hematol       Date:  2022-03-11       Impact factor: 13.265

6.  High expression levels of TLR9 and PD-L1 indicates a poor prognosis in patients with angioimmunoblastic T-cell lymphoma: a retrospective study of 88 cases in a single center.

Authors:  Jingrong Qian; Hongxue Meng; Bowen Lv; Jie Wang; Yingying Lu; Liju Su; Shu Zhao; Wenhui Li
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207

7.  Therapeutic Effect of CAOLD Chemotherapy Regimen on Patients With Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma: A Case Study.

Authors:  Yu Liu; Pingping Li; Liren Qian
Journal:  Front Oncol       Date:  2022-01-03       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.